National Cancer Institute (NCI)

Summary

National Cancer Institute (NCI) is a medical facility located in Bethesda, Maryland. This center is recognized for care of Cancer, Pancreatic Cancer, Breast Cancer, Melanoma, Tumors and other specialties. National Cancer Institute (NCI) is involved with conducting 296 clinical trials across 393 conditions. There are 11 research doctors associated with this hospital, such as A P. Chen, Nirali N. Shah, John Glod, MD, and Deborah Citrin, MD.

Top PIs

Clinical Trials running at National Cancer Institute (NCI)

Cancer

Prostate Cancer

Skin Cancer

Melanoma

Bladder Cancer

Small Cell Lung Cancer

Kidney Cancer

Hairy Cell Leukemia

Peripheral Nerve Sheath Tumor

Lung Cancer

GM T Cell Therapy Long-Term Follow-Up

for Cancer

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Recruiting

1 award

Phase 2 & 3

ANK-101

for Cancer

This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed during or after receiving standard of care (SOC) therapy or who will not benefit from such therapy. The study will be conducted in three parts; in Part 1, participants with superficial lesions will receive ANK-101 as a single agent; in Part 2, participants with visceral lesions will receive ANK-101 as a single agent; and in Part 3, participants with cutaneous squamous cell carcinoma (CSCC) will receive ANK-101 in combination with cemiplimab.

Recruiting

1 award

Phase 1

Olaparib

for Bladder Cancer

This trial studies how well olaparib works in patients with advanced bladder and other genitourinary cancers that have DNA-repair defects. Olaparib is a drug that stops cancer cells from fixing their damaged DNA, which can help to stop the cancer from growing. The trial targets patients whose cancers have spread and are not responsive to standard treatments.

Recruiting

1 award

Phase 2

20 criteria